New Developments in Myeloma, an Issue of Hematology/Oncology Clinics of North America

In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.

Molecular Pathogenesis of Multiple Myeloma: Clinical ImplicationsImmune-Pathogenesis of MyelomaSmoldering Multiple Myeloma: Observation Versus Control Versus CureCereblon-targeting ligase degraders in myeloma: Mechanisms of action and resistanceProteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional GenomicsMonoclonal Antibodies in the Treatment of Multiple MyelomaBispecific Antibodies in the Treatment of Multiple MyelomaChimeric Antigen Receptor T Cells in the Treatment of Multiple MyelomaIs There Still a Role for Stem Cell Transplantation in Multiple Myeloma?Role of Consolidation and MaintenanceManagement of Newly Diagnosed Multiple Myeloma Today, and in the FutureImpact of Clonal Heterogeneity in Multiple MyelomaMeasurable Residual Disease and Decision-Making in Multiple MyelomaApproach to High-Risk Multiple MyelomaNew Therapies on the Horizon for Relapsed Refractory Multiple MyelomaImmunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications